Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:ICOCVE:PAS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICOiCo TherapeuticsC$0.11C$0.11C$0.02▼C$0.16C$952KN/A3.16 million shs1.31 million shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICOiCo Therapeutics0.00%0.00%0.00%0.00%0.00%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICOiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICOiCo TherapeuticsN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICOiCo TherapeuticsN/AN/AC$0.01 per share8.75C$0.00 per shareN/APASPascal BiosciencesN/AN/AC$0.00 per share55.00C($0.02) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICOiCo TherapeuticsN/A-C$0.01N/A∞N/AN/AN/AN/AN/APASPascal BiosciencesN/A-C$0.01N/A∞N/AN/AN/A-340.40%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICOiCo TherapeuticsN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICOiCo TherapeuticsN/A1.141.12PASPascal Biosciences882.790.030.17OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICOiCo TherapeuticsN/APASPascal BiosciencesN/AInsider OwnershipCompanyInsider OwnershipICOiCo TherapeuticsN/APASPascal Biosciences15.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableICOiCo TherapeuticsN/A9.07 millionN/ANot OptionablePASPascal Biosciences665.59 millionN/ANot OptionableLCT, PAS, ICO, MTPH, and MEB HeadlinesSourceHeadlineEdwards gets Q1 boost as Pascal valve repair sales ramp upmedtechdive.com - April 26 at 2:01 PMPacers' Pascal Siakam has been a matchup nightmare for Bucksmsn.com - April 26 at 9:01 AMNBA Playoff Props: Will Pascal Siakam Keep Up Historic Playoff Start?msn.com - April 26 at 9:01 AMPascal Siakam entered the playoffs wanting to be the Indiana Pacers leader. He left Milwaukee on top of the league.si.com - April 25 at 2:53 PMPascal Siakam shouts out Pacers fans after monster Game 2 outing vs. Bucksmsn.com - April 24 at 3:47 PMThis is why Pacers traded for Pascal Siakam: Spicy P has been best player not named Jokic in 2024 NBA Playoffssportingnews.com - April 24 at 3:47 PMPascal Siakam 6th NBA Player to Record These Stats in Playoff Game With 0 Turnoversbasketballinsiders.com - April 24 at 3:47 PMPascal Siakam NBA Playoff history, stats, appearances and recordftw.usatoday.com - April 24 at 10:47 AMPascal Siakam provides Pacers steadying force and voice with 37 points in Game 2 winmsn.com - April 24 at 10:47 AMHow Pascal Siakam’s voice — and game —led the Pacers to evening series with Bucksusatoday.com - April 24 at 10:47 AMPascal Siakam Player Prop Bets: Pacers vs. Bucks | April 26sportsbookwire.usatoday.com - April 24 at 10:47 AMPascal Siakam leads Pacers offense in win, evens series with Buckswishtv.com - April 24 at 5:47 AMBrighton's Pascal Gross is 'best player I have played with'theargus.co.uk - April 24 at 5:47 AMPascal Siakam Reaches Wilt Chamberlain Territory With Dominant Playoff Startgivemesport.com - April 24 at 5:47 AMPacers forward Pascal Siakam discusses his 37-point out in a win over the Bucks in Game 2.indystar.com - April 24 at 5:47 AMPascal Siakam helps the Pacers tie serires up at 1-1 against Buckshoopshype.com - April 24 at 12:29 AMPascal Siakam with 37 Points vs. Milwaukee Bucksnba.com - April 24 at 12:29 AMPascal Siakam scores and draws the foulsports.yahoo.com - April 24 at 12:29 AMPascal Siakam puts up 37 as Pacers pull level with Bucksreuters.com - April 24 at 12:29 AMPascal Siakam helps the Pacers tie series up at 1-1 against Buckshoopshype.com - April 24 at 12:29 AMPascal Siakam leads resurgent Pacers offense in 125-108 victory that evens series with Bucksmsn.com - April 24 at 12:29 AMPascal Siakam Wows NBA Fans as Haliburton, Pacers Beat Lillard, Bucks Without Giannisbleacherreport.com - April 24 at 12:29 AMA Matt Damon And Pedro Pascal Movie Flop From 2017 Is Coming To Netflix In Mayforbes.com - April 23 at 7:29 PMPascal Fratellia leaves Olympics role at EBUtvbeurope.com - April 23 at 9:28 AMMedia Sentiment Over TimeTop HeadlinesBreakout Alert: Coinbase's Consolidation Is About To EndApril 12, 2024 9:45 AMView Breakout Alert: Coinbase's Consolidation Is About To EndWendy’s Stock Could Be Your Best Passive Income StockApril 9, 2024 7:45 AMView Wendy’s Stock Could Be Your Best Passive Income Stock5 Semiconductor Giants: Navigating the Recent PullbackApril 12, 2024 9:10 AMView 5 Semiconductor Giants: Navigating the Recent PullbackASML’s Earnings Could Bring The Stock to New HighsApril 16, 2024 10:20 AMView ASML’s Earnings Could Bring The Stock to New Highs5 Trends You Need to Know This QuarterApril 13, 2024 9:16 AMView 5 Trends You Need to Know This QuarterAll Headlines Company DescriptionsiCo TherapeuticsCVE:ICOiCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.Pascal BiosciencesCVE:PASPascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
